• Home  /
  • Research & Analysis   /
  • Two Top Stories of Wall Street: First Bancorp (NYSE:FBP), Nektar Therapeutics (NASDAQ:NKTR)

Two Top Stories of Wall Street: First Bancorp (NYSE:FBP), Nektar Therapeutics (NASDAQ:NKTR)

First Bancorp (NYSE:FBP)

The shares of First Bancorp (NYSE:FBP) started off the last trading session with the price of $6.2 while closing the day with the price of $6.05. The shares of First Bancorp (NYSE:FBP) Fell -3.82% with the Loss of -0.15 points.

The shares of First Bancorp (NYSE:FBP) traded with the day volume of 1.82 Million shares whereas its average trading volume is 1.93 Million.

While analyzing the past performance of the stock we can see that the shares of First Bancorp (NYSE:FBP) Loss -5.32% in the last week while Falling -1.94% in the last month. Past quarter performance shows the green light with 21.73%. The semi-annual and annual performance shows 9.8% and 12.24% respectively.

Some critical values of the shares of First Bancorp (NYSE:FBP) to be discussed here are: the beta which shows the value at 1.83 while Average True Range of First Bancorp (NYSE:FBP) demonstrate the value at 0.18. The weekly and monthly volatility of the shares of First Bancorp (NYSE:FBP) are indicated at 2.87% and 2.77%. Also to discuss here is the Relative Strength Index or RSI which is depicted at 44.11.

While studying the financial position of the shares of First Bancorp (NYSE:FBP), we can see that the Market capitalization of the company is at 1.29 Billion. The shares outstanding for the company is 213.93 Million and the shares float stands at 201.74 Million. The income of the company stand at 64.3 Million while the sales stand at 588.4 Million.

Here are some critical ratios for a financial perspective: Earnings Per Share or EPS of the company stand at 0.3, Price to Earnings or P/E is at 20.44, Price to Sales P/S show the value of 2.2, the Return on Asset ROA stood at 0.005 and the Return on Equity ROE depicted at 0.035 while Return on Investment ROI is at 0.173.


Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ:NKTR) started its previous trading session at $105.71 and closed at $104.01 showing a Fell of -2.71 Percent.

The Company traded with an average Volume of 3.21 Million whereas, its Day Volume stood at 1.82 Million.

Looking at the performance of the stock, Nektar Therapeutics (NASDAQ:NKTR) Gain 1.96% in the last week in its shares price and 20.31% in the last month. Quarterly performance shows a green of 82.31 Percent while Semi-Annual and Annual performances shows a 386.26 and 354.39 percent respectively.

Beta for Nektar Therapeutics (NASDAQ:NKTR) stands at 1.91 while the ATR (average true range) is at 5.37. The Stock’s Weekly and Monthly Volatility is 3.75% and 5.46% respectively showing a RSI value of 60.09.

While studying the financial position of the shares of Nektar Therapeutics (NASDAQ:NKTR), we can see that the Market capitalization of the company is at 16.58 Billion. The shares outstanding for the company is 159.38 Million and the shares float stands at 159.38 Million.

The Company generated an income of -96700000 and the sales of 307.7 Million in the Trailing Twelve Months period.

While analyzing the stock from technical aspects, Diluted Earnings per share stands at $-0.64 a share. P/E (price to earnings) and P/S (price to sales) values are 0 and 53.87 respectively.

The Return on Assets stands at -0.185, ROE shows a value of -1.757 and ROI for Nektar Therapeutics (NASDAQ:NKTR) is -0.181 as of Trailing Twelve Months period.

The following two tabs change content below.

Eldred Matthew

Eldred Matthew covers Healthcare Sector Company recent Press Releases news updates. He has three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a comment